Rises in non-submissions to NICE: do they matter?Leela Barham asks why companies may choose to not submit their drugs to NICE and keep them off Share XRises in non-submissions to NICE: do they matter?https://pharmaphorum.com/views-analysis-market-access/rises-in-non-submissions-to-nice-do-they-matter/
Getting the most out of technical engagement with NICEIn 2017 the UK’s National Institute for Health and Care Excellence (NICE) consulted on changes to help the Share XGetting the most out of technical engagement with NICEhttps://pharmaphorum.com/views-analysis-market-access/getting-the-most-out-of-technical-engagement-with-nice/
COVID-19 puts NHS’ app library to the testLeela Barham looks at how apps with the NHS’ seal of approval are faring in the market and Share XCOVID-19 puts NHS’ app library to the testhttps://pharmaphorum.com/views-and-analysis/covid-19-puts-nhs-app-library-to-the-test/
Simple steps to better communicate NHS medicines spendLeela Barham says that there’s a communication problem when it comes to one of the most important and Share XSimple steps to better communicate NHS medicines spendhttps://pharmaphorum.com/views-analysis-market-access/simple-steps-better-communicate-nhs-medicines-spend/
Future prospects for an Innovative Medicines Fund for EnglandOn the 12 December 2019, the UK general public voted for a further five years of Conservative government. Share XFuture prospects for an Innovative Medicines Fund for Englandhttps://pharmaphorum.com/views-analysis-market-access/future-prospects-for-an-innovative-medicines-fund-for-england/
An alternative set of metrics for the UK’s pricing and access dealLeela Barham takes a look at alternative ways pharma and the UK government could measure progress for the Share XAn alternative set of metrics for the UK’s pricing and access dealhttps://pharmaphorum.com/views-and-analysis/an-alternative-set-of-metrics-for-the-uks-pricing-and-access-deal/
Secret US-UK talks on drug pricing revealedDespite the UK still not leaving the European Union – pencilled in for the 31 January 2020 at Share XSecret US-UK talks on drug pricing revealedhttps://pharmaphorum.com/views-analysis-market-access/secret-us-uk-talks-on-drug-pricing-revealed/
Nice numbers at 20: what end-of-life evidence does NICE draw on?NICE may be 20 this year, but its policy on end-of-life (EoL) treatments – where NICE can recommend Share XNice numbers at 20: what end-of-life evidence does NICE draw on?https://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-what-end-of-life-evidence-does-nice-draw-on/
NICE numbers at 20: trends in dealsNICE provides a downloadable excel file of details of Technology Appraisal (TAs) recommendations which can help explore trends Share XNICE numbers at 20: trends in dealshttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-trends-in-deals/
